Retroviruses use different IP6 binding mechanisms to alter the properties of their capsids
Abstract HIV-1 uses the metabolite inositol hexakisphosphate (IP 6 ) as a host factor to assemble its capsid, but whether this strategy is unique to lentiviruses or represents a common feature of retroviral capsids remains unclear. Here we show that IP 6 binding is conserved across diverse retroviruses but occurs through distinct capsid sites and mechanisms, and influences viral behaviour. In contrast to HIV-1, the beta-retrovirus Mason-Pfizer Monkey Virus (MPMV) and the gamma-retrovirus Murine Leukaemia Virus (MLV) bind IP 6 at the threefold lattice interface between capsomers rather than within capsomer pores. Cryo-EM structures of core-like particles reveal that two lysine residues from each capsomer coordinate IP 6 between either two discrete three-lysine rings (MPMV) or a single heterogeneous six-lysine ring (MLV). MPMV and MLV are largely insensitive to IP 6 availability in producer cells, but this binding mode renders them highly dependent on IP6 in target cells – the opposite of the dependency pattern of HIV-1. The way in which retroviruses use IP 6 to build their capsids alters their dependence on the metabolite at different stages of the replicative cycle and in key capsid behaviours, such as assembly and stability.
Authors
- John A. G. Briggs (ORCID: https://orcid.org/0000-0003-3990-6910)
- Davide Torre (ORCID: https://orcid.org/0000-0002-7072-0578)
- James C. V. Stacey (ORCID: https://orcid.org/0000-0003-2484-8738)
- Tomáš Ruml (ORCID: https://orcid.org/0000-0002-5698-4366)
- Leo C. James (ORCID: https://orcid.org/0000-0003-2131-0334)
- Michaela Rumlová (ORCID: https://orcid.org/0000-0002-5645-8227)
- Donna L. Mallery (ORCID: https://orcid.org/0000-0003-2713-5215)
- J Ole Klarhof
Institutions
- MRC Laboratory of Molecular Biology (GB)
- Max Planck Institute of Biochemistry (DE)
- University of Chemistry and Technology, Prague (CZ)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-08-21
- DOI
- https://doi.org/10.1038/s41467-026-76510-7
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wellcome Trust
- European Commission
- Max-Planck-Gesellschaft
- Medical Research Council